Scarletred

28/02/2026

🦋 We stand with patients, families, researchers, and clinicians worldwide — every day. 🦋

🫂 Today, on Rare Disease Day, we reaffirm our mission: advancing digital dermatology and improving care for rare diseases.

🗞️ We are honored to be featured in the nationwide journal (Seltene Krankheiten) for our 3D dermatology innovation in (EB).

affects roughly one in 50,000 births worldwide.
🔺 “Butterfly children” face extremely fragile skin, chronic wounds, and risks of serious complications.
🔺 Frequent hospital visits can be painful, stressful, and exhausting.

Scarletred®Vision is designed to change that — bringing safe, precise skin monitoring into patients’ homes:

🔎 A single smartphone image turns into a reliable clinical dataset – enabling mobile monitoring from home.
🔎 Scarletred®Vision detects, quantifies and monitors EB blisters over time.
🔎 This supports early intervention, treatment decisions, and improved wound care.

🛎 Stay tuned for more updates & read more in our article!

Scarletred®Vision enables 3D Assessment and Monitoring in Epidermolysis Bullosa (EB) with ARORA®AI. Beyond the detection of blisters, Scarletred®Vision assesses their stage and precisely measures their area, depth and volume.

25/02/2026

💉The rapid rise of ® and other GLP-1 receptor agonists is reshaping modern medicine. 💉

⚖️ What began as a therapy for type 2 diabetes is now widely used for weight management — with rapidly growing adoption across the US and Europe.

🔬 Alongside its clinical success, a new phenomenon has entered the discussion: ® Face.

🔺 ® Vision enables standardized digital skin imaging and quantitative analysis using smartphones — transforming visual changes into clinically actionable data.

🔎 Early detection supports informed clinical decisions, personalized aesthetic strategies, and structured longitudinal monitoring.

🔬As metabolic medicine evolves, so shall the tools we use to understand its dermatological impact.

🔗 Read about the Ozempic® Face and how Scarletred® Vision helps with detection and monitoring in our article.

Ozempic® is a GLP-1 therapy known for rapid weight loss, but it can also cause facial changes often referred to as Ozempic® Face. Scarletred® Vision allows early detection and monitoring of these changes.

17/09/2025

🇫🇷 We’re excited to announce our participation in from 17-20 September. Our team will be presenting two cutting-edge AI studies focused on transforming how skin conditions are objectively analysed and classified:

📌 Beyond Redness: AI-Driven Profiling of Rosacea Severity and Morphological Markers

📌 Objective Skin Typing Across the Spectrum: AI-Driven Fitzpatrick Classification from Facial Imagery

📩 Want to connect at the congress? Reach us at office@scarletred.



EADV - European Academy of Dermatology and Venereology Wirtschaftskammer Startups Go Global - Aussenwirtschaft Austria Austria Wirtschaftsservice Stadt Wien

30/05/2025

🤖 SCARLETRED unveils Arora AI at Expo2025 大阪・関西万博 Japan: Redefining the future of digital skin analysis! 🇯🇵✨

Now integrated into our new service Scarletred® Vision+, Arora AI delivers automated, AI-powered skin disease assessment that’s faster, smarter, for use in clinics, clinical trials, and remote care settings.

From psoriasis to alopecia and wound care, Arora AI adapts to all skin types and environments with unmatched precision.

📍 Experience Scarletred@Vision live at the Austrian Pavilion, EXPO 2025 Osaka
📩 Get in touch: office@scarletred.com

SCARLETRED unveils Aurora AI at EXPO 2025 Japan, an intelligent assistant integrated into our new service Scarletred®Vision+, automating skin disease analysis with unmatched speed, accuracy, and real-world usability.

26/05/2025

🔬 Just one day to go!

We’re excited to return as Expertise Partner at the 6th Annual Dermatology Drug Development Summit Europe 2025 in Berlin, starting tomorrow!

📍 Don’t miss our CEO Dr. Harald Schnidar speaking on the main stage at 11:30 AM, sharing insights on AI-powered innovation in dermatology drug development.

See you there!

22/05/2025

🔬SCARLETRED is heading to EADV Spring Symposium 2025 in Prague, 22–24 May!

Our team will be on-site from tomorrow, presenting two cutting-edge research posters powered by Scarletred® Vision, featuring AI-driven innovations in Alopecia Areata and Epidermolysis Bullosa.

📍 Join us in Prague and explore how digital innovation is transforming dermatology research.

SCARLETRED will attend the EADV Spring Symposium 2025 in Prague to present new research, showcasing our latest advancements in AI-driven dermatology and digital skin analysis about Alopecia areata and Epidermolysis bullosa.

13/05/2025

📚 Bridging academia and industry with AI-driven innovation!

SCARLETRED CEO Dr. Harald Schnidar is speaking today at MedUni Vienna, highlighting how digital health innovation and AI-powered platforms like Scarletred® Vision are shaping the future of academic R&D.

📍 Seminar: From Academia to Industry
🗓️ 13th of May, 14:00 | Seminar Room 06.L1.08 | Vienna General Hospital (AKH)

Proud to support the next generation of clinical research and digital health innovation!

SCARLETRED CEO Dr. Harald Schnidar speaks at MedUni Vienna on connecting academia and industry, showcasing how AI and SaaS solutions like Scarletred®Vision drive innovation in skin drug research and clinical development.

29/04/2025

🌸 We’re proud to sponsor the Cherry Blossom Business & Culture Event on May 9, 2025, at the Vienna Airport Conference & Innovation Center! 🇦🇹🇯🇵

Join us for a full day of Austria-Japan business networking, cultural exchange, panel discussions, concerts, and a live video connection to the Austrian Pavilion at EXPO 2025 Osaka, where Scarletred is proudly represented! 🎌✨

📍 Time: 9:30–17:00
🎟️ Register now: airportcity.at/cherry-blossom

Let's build bridges between innovation, culture, and global collaboration! 🌍

14/04/2025

🇦🇹✨ EXPO 2025 has officially begun, and we're thrilled to be part of it! ✨🇯🇵

We're proud to represent Scarletred in the Austrian Pavilion, showcasing innovation in digital health.

🎌 Come visit us and experience the future of AI-powered dermatology firsthand!
See you at EXPO 2025!

11/04/2025

🚨 We’re back at Dermatology Drug Development Summit Europe 2025 as an Expertise Partner!

Join us in Berlin, May 27–28, and see how Scarletred® Vision is transforming clinical trials with AI-powered skin imaging.

🎯 Visit our booth & connect with our team

🔥 Receive a 20% off discount with promo code SCARLETRED20, available exclusively for our network via office@scarletred.com!

Scarletred joins the 6th Dermatology Drug Development Summit Europe 2025 in Berlin as Expertise Partner, showcasing AI-powered skin imaging and innovation in clinical trials with Scarletred®Vision.

09/04/2025

🌹 April is Rosacea Awareness Month

Persistent facial redness, changes in texture, or visible veins? These could be signs of rosacea, a chronic inflammatory skin condition that requires precise diagnosis and continuous monitoring.

With SCARLETRED® Vision, clinicians and researchers can objectively track rosacea progression using standardized imaging and AI-powered analysis. 🔬📊

📣 Let’s raise awareness this April and support smarter tools for early detection and personalized care.

📖 Dive deeper into our research on Ivermectin therapy for rosacea here:
https://bit.ly/4lnDjUn



https://www.scarletred.com/articles/rosacea-objective-standardized-analysis-quantitative-assessment-of-erythema-and-skin-texture-alterations

Being a chronic inflammatory skin disorder, patients with rosacea need standardized tools, as provided by SCARLETRED, to improve the condition’s analysis and treatment and overcome psychosocial stigmatization.